UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety

被引：4
|
作者：
Peeters, Sofia L. J. [1 ,2 ]
Deenen, Maarten J. [1 ,2 ]
Thijs, Anna M. J. [3 ]
Hulshof, Emma C. [1 ,2 ]
Mathijssen, Ron H. J. [4 ]
Gelderblom, Hans [5 ]
Guchelaar, Henk-Jan [2 ]
Swen, Jesse J. [2 ]
机构：
[1] Catharina Hosp, Dept Clin Pharm, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[3] Catharina Hosp, Dept Med Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[4] Erasmus MC, Dept Med Oncol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] Leiden Univ, Dept Med Oncol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
来源：
PHARMACOGENOMICS | 2023年 / 24卷 / 09期
关键词：
irinotecan; personalized medicine; PGx; pharmacogenetics; pharmacogenomics; precision dosing; pretreatment; UGT1A1; PHARMACOGENETICS; IMPLEMENTATION; NEUTROPENIA; TOXICITY; THERAPY; RISK;
D O I：
10.2217/pgs-2023-0096
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care. © 2023 Future Medicine Ltd.
引用
收藏
页码：435 / 439
页数：5
相关论文
共 50 条
  • [41] UGT1A1*20 and other UGT1A polymorphisms as determinants of irinotecan toxicity
    Biason, P.
    Masier, S.
    Toffoli, G.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (02) : 158 - 165
  • [42] Invader UGT1A1 Molecular Assay for irinotecan toxicity
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2006, 48 (1234): : 39 - 40
  • [43] A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer
    Sanoff, Hanna K.
    Deal, Allison M.
    Patel, Jai
    Sorah, Jonathan D.
    Gaddy, Jacquelyne
    O'Neil, Bert
    Turk, Anita
    Irvin, William
    Boles, Jeremiah
    Lee, Michael S.
    McRee, Autumn
    Wardell, Alexis C.
    Weck, Karen E.
    Basch, Ethan
    Wood, William A.
    Innocenti, Federico
    ONCOLOGIST, 2024, 29 (09): : 786 - 793
  • [44] UGT1A1*6 AND UGT1A1*27 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE NEUTROPENIA IN JAPANESE PATIENTS WITH NSCLC
    Doi, S.
    Nakamura, Y.
    Fukuda, M.
    Takatani, H.
    Fukuda, M.
    Kinoshita, A.
    Soda, H.
    Oka, M.
    Tsukamoto, K.
    Kohno, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 165 - 165
  • [45] Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
    Deng Bo
    Jia Liqun
    Tan Huangying
    Lou Yanni
    Li Xue
    Li Yuan
    Yu Lili
    Journal of Traditional Chinese Medicine, 2017, 37 (01) : 35 - 42
  • [46] UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan
    Ferraldeschi, Robert
    Minchell, Laura J.
    Roberts, Stephen A.
    Tobi, Simon
    Hadfield, Kristen D.
    Blackhall, Fiona H.
    Mullamitha, Saifee
    Wilson, Gregory
    Valle, Juan
    Saunders, Mark
    Newman, William G.
    PHARMACOGENOMICS, 2009, 10 (05) : 733 - 739
  • [47] UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis
    Yang, Yuwei
    Zhou, MengMeng
    Hu, Mingjun
    Cui, Yanjie
    Zhong, Qi
    Liang, Ling
    Huang, Fen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (05) : e479 - e489
  • [48] Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum
    Takano, Masashi
    Yamamoto, Kaichiro
    Tabata, Tsutomu
    Minegishi, Yuji
    Yokoyama, Takuma
    Hirata, Eiji
    Ikeda, Takeshi
    Shimada, Muneaki
    Yamada, Kouzo
    Morita, Satoshi
    Ando, Yuichi
    Hirata, Koji
    Sugihara, Masahiro
    Sugiyama, Toru
    Ohashi, Yasuo
    Sakata, Yuh
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (02) : 115 - 124
  • [49] The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
    Chen, Yi-Jing
    Hu, Fei
    Li, Chun-Yan
    Fang, Jue-Min
    Chu, Li
    Zhang, Xi
    Xu, Qing
    BIOMARKERS, 2014, 19 (01) : 56 - 62
  • [50] The UGT1A1*28 Genotype and the Toxicity of Low-Dose Irinotecan in Patients With Advanced Lung Cancer
    Sugiyama, Tomohide
    Hirose, Takashi
    Kusumoto, Sojiro
    Shirai, Takao
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Adachi, Mitsuru
    ONCOLOGY RESEARCH, 2009, 18 (07) : 337 - 342
12345